Table 1.
Demographic and HIV-related characteristics of 491 participants aged 10–24 years receiving ART across Cape Town, November 2018–March 2019
| Characteristic | N = 491a | Median (IQR) or n (%)b | |
|---|---|---|---|
| Demographics | Age at folder review (years) | 20 (14–23) | |
| Male | 127 (26%) | ||
| HIV-related | |||
| HIV management | Age at ART initiation (years) | 473 (96%) | 18 (6–21) |
| Duration on ART (years) | 471 (96%) | 3.1 (1.1–8.9) | |
| CD4 count (cells/mm3) | 395 (80%) | 489 (355 --690) | |
| Viral suppression (< 20 copies/ml) | 369 (75%) | 256 (69%) | |
| Current ART regimenc | First line: ABC 3TC EFV | 84 (17%) | |
| TDF FTC EFV | 298 (61%) | ||
| Second line: ABC 3TC LPV/r | 39 (8%) | ||
| AZT 3TC LPV/r | 29 (6%) | ||
| Other regimens | 41 (8%) | ||
| HIV opportunistic infections | 28 (6%) | ||
| Herpes zoster (shingles) | 11 (39%) | ||
| Pruritic papular eruption | 8 (29%) | ||
| Oral thrush | 2 (7%) | ||
| Oral candida | 2 (7%) | ||
| Oral hairy leucoplakia | 1 (3.6%) | ||
| Oesophageal candidiasis | 1 (3.6%) | ||
| Pneumocystis jirovecii pneumonia | 1 (3.6%) | ||
| HIV Encephalopathy | 1 (3.6%) | ||
| Cytomegalovirus disease | 1 (3.6%) | ||
| ART-related conditionsd | 8 (2%) | ||
| AZT-neutropenia | 1 (13%) | ||
| D4T-lipodystrophy, lipoatrophy | 7 (87%) | ||
aDenominator = 491, unless otherwise indicated in this column; bPercentages may not total 100 due to rounding; cCurrent ART regimens: ABC Abacavir, 3TC lamivudine, EFV efavirenz, TDF tenofovir, FTC emtricitabine, LPV/r lopinavir/ritonavir; dART-related conditions: AZT zidovudine, D4T stavudine